Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Integration of Biomedical and Psychosocial Treatments in Pediatrics Functional Gastrointestinal Disorders.

van Tilburg MAL, Carter CA.

Gastroenterol Clin North Am. 2018 Dec;47(4):863-875. doi: 10.1016/j.gtc.2018.07.010. Epub 2018 Sep 28. Review.

PMID:
30337037
2.

Structural basis for targeting avian sarcoma virus Gag polyprotein to the plasma membrane for virus assembly.

Vlach J, Eastep GN, Ghanam RH, Watanabe SM, Carter CA, Saad JS.

J Biol Chem. 2018 Dec 7;293(49):18828-18840. doi: 10.1074/jbc.RA118.003944. Epub 2018 Oct 11.

PMID:
30309983
3.

The matrix domain of the Gag protein from avian sarcoma virus contains a PI(4,5)P2-binding site that targets Gag to the cell periphery.

Watanabe SM, Medina GN, Eastep GN, Ghanam RH, Vlach J, Saad JS, Carter CA.

J Biol Chem. 2018 Dec 7;293(49):18841-18853. doi: 10.1074/jbc.RA118.003947. Epub 2018 Oct 11.

PMID:
30309982
4.

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs).

Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR.

Oncoimmunology. 2018 Jul 23;7(9):e1478648. doi: 10.1080/2162402X.2018.1478648. eCollection 2018. Review.

PMID:
30228948
5.

Remunerated patient care services and injections by pharmacists: An international update.

Houle SKD, Carter CA, Tsuyuki RT, Grindrod KA.

J Am Pharm Assoc (2003). 2019 Jan - Feb;59(1):89-107. doi: 10.1016/j.japh.2018.07.002. Epub 2018 Sep 6.

PMID:
30195440
6.

Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer.

Oronsky B, Larson C, Reid TR, Carter CA.

J Investig Med High Impact Case Rep. 2018 Jul 6;6:2324709618786319. doi: 10.1177/2324709618786319. eCollection 2018 Jan-Dec.

7.

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P.

Oncotarget. 2018 May 4;9(34):23439-23442. doi: 10.18632/oncotarget.25211. eCollection 2018 May 4.

8.

Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER Population.

Lin J, Kamamia C, Brown D, Shao S, McGlynn KA, Nations JA, Carter CA, Shriver CD, Zhu K.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):673-679. doi: 10.1158/1055-9965.EPI-17-0822. Epub 2018 Mar 12.

PMID:
29531129
9.

The Genetics of Food Allergy.

Carter CA, Frischmeyer-Guerrerio PA.

Curr Allergy Asthma Rep. 2018 Jan 26;18(1):2. doi: 10.1007/s11882-018-0756-z. Review.

PMID:
29374367
10.

Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors.

Tien C, Huang L, Watanabe SM, Speidel JT, Carter CA, Chen C.

PLoS One. 2018 Jan 16;13(1):e0191372. doi: 10.1371/journal.pone.0191372. eCollection 2018.

11.

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

Oronsky B, Ma P, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA.

Neoplasia. 2018 Jan;20(1):92-98. doi: 10.1016/j.neo.2017.11.001. Epub 2017 Dec 8. Review.

12.

No patient left behind: The promise of immune priming with epigenetic agents.

Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR.

Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Review.

13.

Tsg101 chaperone function revealed by HIV-1 assembly inhibitors.

Strickland M, Ehrlich LS, Watanabe S, Khan M, Strub MP, Luan CH, Powell MD, Leis J, Tjandra N, Carter CA.

Nat Commun. 2017 Nov 9;8(1):1391. doi: 10.1038/s41467-017-01426-2.

14.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Oronsky B, Ma PC, Morgensztern D, Carter CA.

Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Review.

15.

Food protein-induced enterocolitis syndrome to peanut with early introduction: a clinical dilemma.

Robbins KA, Ackerman OR, Carter CA, Uygungil B, Sprunger A, Sharma HP.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):664-666. doi: 10.1016/j.jaip.2017.06.038. Epub 2017 Sep 6. No abstract available.

PMID:
28888843
16.

What's New in SCLC? A Review.

Oronsky B, Reid TR, Oronsky A, Carter CA.

Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6. Review.

17.

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.

Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA.

Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Review.

18.

A Review of Control Options and Externalities for Verticillium Wilts.

Carroll CL, Carter CA, Goodhue RE, Lawell CCL, Subbarao KV.

Phytopathology. 2018 Feb;108(2):160-171. doi: 10.1094/PHYTO-03-17-0083-RVW. Epub 2017 Oct 16. Review.

PMID:
28703041
19.

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.

Brzezniak C, Oronsky B, Carter CA, Thilagar B, Caroen S, Zeman K.

Case Rep Oncol. 2017 Mar 17;10(1):252-257. doi: 10.1159/000464278. eCollection 2017 Jan-Apr.

20.

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.

Brzezniak CE, Vietor N, Hogan PE, Oronsky B, Thilagar B, Ray CM, Caroen S, Lybeck M, Oronsky N, Carter CA.

Case Rep Oncol. 2017 Apr 6;10(1):321-324. doi: 10.1159/000467390. eCollection 2017 Jan-Apr.

21.

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

Brzezniak C, Oronsky B, Trepel J, Summers TA Jr, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA.

Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

22.

Recalcitrant small cell lung cancer: the argument for optimism.

Zeman KG, Brzezniak CE, Carter CA.

J Thorac Dis. 2017 Mar;9(3):E295-E296. doi: 10.21037/jtd.2017.03.40. No abstract available.

23.

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM.

Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. Review.

PMID:
28444622
24.

RRx-001 protects against cisplatin-induced toxicities.

Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17.

PMID:
28417195
25.

A Scoping Review of Frailty and Acute Care in Middle-Aged and Older Individuals with Recommendations for Future Research.

Hogan DB, Maxwell CJ, Afilalo J, Arora RC, Bagshaw SM, Basran J, Bergman H, Bronskill SE, Carter CA, Dixon E, Hemmelgarn B, Madden K, Mitnitski A, Rolfson D, Stelfox HT, Tam-Tham H, Wunsch H.

Can Geriatr J. 2017 Mar 31;20(1):22-37. doi: 10.5770/cgj.20.240. eCollection 2017 Mar. Review.

26.

Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system.

Lin J, Gill A, Zahm SH, Carter CA, Shriver CD, Nations JA, Anderson WF, McGlynn KA, Zhu K.

Int J Cancer. 2017 Jul 15;141(2):254-263. doi: 10.1002/ijc.30724. Epub 2017 May 4.

27.

Stage-specific, Nonlinear Surface Ozone Damage to Rice Production in China.

Carter CA, Cui X, Ding A, Ghanem D, Jiang F, Yi F, Zhong F.

Sci Rep. 2017 Mar 13;7:44224. doi: 10.1038/srep44224.

28.

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.

Horn L, Wakelee H, Reckamp KL, Blumenschein G Jr, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM.

J Thorac Oncol. 2016 Nov;11(11S):S256-S257. doi: 10.1016/j.jtho.2016.09.017. Epub 2016 Oct 28. No abstract available.

29.

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.

Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review. Erratum in: Expert Opin Investig Drugs. 2017 Feb;26(2):261. Carterg, Corey A [corrected to Carter, Corey A].

30.

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001263.

31.

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.

Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

PMID:
27855386
32.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.

Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

33.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.

Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205. Review.

34.

The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.

Watanabe SM, Simon V, Durham ND, Kemp BR, Machihara S, Kemal KS, Shi B, Foley B, Li H, Chen BK, Weiser B, Burger H, Anastos K, Chen C, Carter CA.

Retrovirology. 2016 Sep 6;13(1):64. doi: 10.1186/s12977-016-0298-1.

35.

The Impact of Preexisting Mental Health Disorders on the Diagnosis, Treatment, and Survival among Lung Cancer Patients in the U.S. Military Health System.

Lin J, McGlynn KA, Carter CA, Nations JA, Anderson WF, Shriver CD, Zhu K.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1564-1571. Epub 2016 Aug 26.

36.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.

Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

37.

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.

Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A.

Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032. Review.

38.

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.

Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.

39.

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

Carter CA, Scicinski JJ, Lybeck HE, Oronsky BT.

Case Rep Oncol. 2016 Apr 23;9(1):246-8. doi: 10.1159/000446064. eCollection 2016 Jan-Apr.

40.

"No patient left behind": an alternative to "the War on Cancer" metaphor.

Oronsky BT, Carter CA, Oronsky AL, Salacz ME, Reid T.

Med Oncol. 2016 Jun;33(6):55. doi: 10.1007/s12032-016-0769-1. Epub 2016 Apr 29.

PMID:
27129923
41.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.

42.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.

Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

43.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.

Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.

44.

Tracheal squamous cell carcinoma (SCC) metastatic to the skin in a patient on a checkpoint inhibitor.

Cassler NM, Marquart JD, Carter CA.

JAAD Case Rep. 2015 Aug 25;1(5):308-9. doi: 10.1016/j.jdcr.2015.07.001. eCollection 2015 Sep. No abstract available.

45.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.

Carter CA, Browning R, Oronsky BT, Scicinski JJ, Brzezniak C.

Case Rep Oncol. 2016 Jan 27;9(1):68-75. doi: 10.1159/000443723. eCollection 2016 Jan-Apr.

46.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.

Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr.

47.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.

Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr.

48.

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G.

Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22.

49.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J.

Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec.

50.

Dysphonia after Bevacizumab Rechallenge: A Case Report.

Carter CA, Caroen SZ, Oronsky AL, Oronsky BT.

Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.

Supplemental Content

Loading ...
Support Center